Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
A multicenter, phase 3, randomized, double-blind, placebo-controlled trial conducted in China, Taiwan, and South Korea1* The functional status of a cancer patient, as assessed by the Eastern Cooperative Oncology Group (ECOG) score.
Treatment with Nexavar or placebo was continued until adverse reactions requiring discontinuation of study treatment, progression of disease, pregnancy, deterioration or ECOG PS to 4, development of an additional form of cancer, withdrawal of consent, or death.RECIST=Response Evaluation Criteria In Solid Tumors;
References: 1. Cheng AL, Yang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34. 2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4)378-390.